Sulphonylurea physicochemical-pharmacokinetic relationships in the pancreas and liver

Journal of Pharmaceutical Sciences

Volumn 98, Issue 8, 2009, Pages 2807-2821

  Fanning, Kent J ^a   Anissimov, Yuri G ^a,b   Roberts, Michael S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Distribution; Log P; Passive diffusion transport; Permeability; Pharmacokinetics; Structure transport relationship

Indexed keywords

ALBUMIN; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; SULFONYLUREA; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG ISOLATION; DRUG PENETRATION; LIPOPHILICITY; LIVER; MALE; NONHUMAN; PANCREAS; PHYSICAL CHEMISTRY; PROTEIN BINDING; RAT;

EID: 68249104353     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21631     Document Type: Article

References (44)

1. Baig NA, Herrine SK, Rubin R. 2001. Liver disease and diabetes mellitus. Clin Lab Med 21:193-207.
2. Fanning KJ, Roberts MS. 2007. Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. Pharm Res 24:512-520.
3. Chou CH, Evans AM, Fornasini G, Rowland M. 1993. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver. Drug Metab Dispos 21:933-938. (Pubitemid 23298462)
4. Mellick GD, Roberts MS. 1999. Structure-hepatic disposition relationships for phenolic compounds. Toxicol Appl Pharmacol 158:50-60.
5. Hung DY, Chang P, Weiss M, Roberts MS. 2001. Structure-hepatic disposition relationships for cationic drugs in isolated perfused rat livers: Transmembrane exchange and cytoplasmic binding process. J Pharmacol Exp Ther 297:780-789. (Pubitemid 32378012)
6. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. 2003. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461. (Pubitemid 37013212)
7. Goresky CA. 1980. Uptake in the liver: The nature of the process. Int Rev Physiol 21:65-101.
8. Chou C, McLachlan AJ, Rowland M. 1995. Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds. J Pharmacol Exp Ther 275:933-940. (Pubitemid 26027052)
9. Goresky CA. 1963. A linear method for determining liver sinusoidal and extravascular volumes. Am J Physiol 204:626-640.
10. Kaku K, Inoue Y, Kaneko T. 1995. Extrapancreatic effects of sulfonylurea drugs. Diabetes Res Clin Pract 28:S105-S108.
11. Boileau P, Wolfrum C, Shih DQ, Yang TA, Wolkoff AW, Stoffel M. 2002. Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor- 1 alpha-deficient mice-A mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3). Diabetes 51:S343-S348. (Pubitemid 35403414)
12. Kamp F, Kizilbash N, Corkey BE, Berggren PO, Hamilton JA. 2003. Sulfonylureas rapidly cross phospholipid bilayer membranes by a free-diffusion mechanism. Diabetes 52:2526-2531. (Pubitemid 37210541)
13. Geng X, Li L, Watkins S, Robbins PD, Drain P. 2003. The insulin secretory granule is the major site of K(ATP) channels of the endocrine pancreas. Diabetes 52:767-776. (Pubitemid 36323585)
14. Petzinger E, Fuckel D. 1992. Evidence for a saturable, energy-dependent and carrier-mediated uptake of oral antidiabetics into rat hepatocytes. Eur J Pharmacol 213:381-391.
15. Weiss M, Roberts MS. 1996. Tissue distribution kinetics as determinant of transit time dispersion of drugs in organs: Application of a stochastic model to the rat hindlimb. J Pharmacokinet Biopharm 24:173-196. (Pubitemid 26300484)
16. Weiss M, Kuhlmann O, Hung DY, Roberts MS. 2000. Cytoplasmic binding and disposition kinetics of diclofenac in the isolated perfused rat liver. Br J Pharmacol 130:1331-1338. (Pubitemid 30488597)
17. Hung DY, Chang P, Cheung K, Winterford C, Roberts MS. 2002. Quantitative evaluation of altered hepatic spaces and membrane transport in fibrotic rat liver. Hepatology 36:1180-1189. (Pubitemid 35253434)
18. Schary WL, Rowland M. 1983. Protein binding and hepatic clearance: Studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation. J Pharmacokinet Biopharm 11:225-243. (Pubitemid 14074002)
19. Munoz M, Sweiry JH, Mann GE. 1995. Insulin stimulates cationic amino acid transport activity in the isolated perfused rat pancreas. Exp Physiol 80:745-753.
20. Holecek M, Rysava R, Safranek R, Kadlcikova J, Sprongl L. 2003. Acute effects of decreased glutamine supply on protein and amino acid metabolism in hepatic tissue: A study using isolated perfused rat liver. Metabolism 52:1062-1067. (Pubitemid 37098378)
21. Hori R, Arakawa M, Okumura K. 1978. Tissue distribution and metabolism of drugs. II. Accumulation and permeation of drugs in the rabbit pancreas. Chem Pharm Bull 26:1135-1140.
22. Roberts MS, Fraser S, Wagner A, McLeod L. 1990. Residence time distributions of solutes in the perfused- rat-liver using a dispersion model of hepatic elimination. 1. Effect of changes in perfusate flow and albumin concentration on sucrose and taurocholate. J Pharmacokinet Biopharm 18:209-234. (Pubitemid 20308931)
23. Weiss M, Ballinger LN, Roberts MS. 1998. Kinetic analysis of vascular marker distribution in perfused rat livers after regeneration following partial hepatectomy. J Hepatol 29:476-481. (Pubitemid 28396667)
24. Foster KA, Mellick GD, Weiss M, Roberts MS. 2000. An isolated in-situ rat head perfusion model for pharmacokinetic studies. Pharm Res 17:127-134. (Pubitemid 30158359)
25. Ouyang Y, Lien EJ. 1984. Quantitative analysis of blood-testis barrier and pancreatic permeation as functions of physiochemical parameters. Acta Pharmaceutica Jugoslavica 34:201-205. (Pubitemid 15198056)
26. Hellman B, Sehlin J, Taljedal IB. 1984. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in betacell- rich pancreatic islets. Acta Endocrinol 105: 385-390. (Pubitemid 14193129)
27. Marynissen G, Smets G, Kloppel G, Gerlache L, Malaisse WJ. 1992. Internalization of glimepiride and glibenclamide in the pancreatic B-cell. Acta Diabetol 29:113-114.
28. Gylfe E, Hellman B, Sehlin J, Taljedal B. 1984. Interaction of sulfonylurea with the pancreatic Bcell. Experientia 40:1126-1134.
29. Rowland M, Tozer TN. 1995. Clinical Pharmacokinetics: Concepts and applications, 3rd edition. Baltimore: Williams and Wilkins.
30. Panten U, Burgfeld J, Goerke F, Rennicke M, Schwanstecher M, Wallasch A, Zunkler BJ, Lenzen S. 1989. Control of insulin-secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic-islets. Biochem Pharmacol 38:1217-1229. (Pubitemid 19101950)
31. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. 2002. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503. (Pubitemid 35397059)
32. Worboys PD, Bradbury A, Houston JB. 1997. Kinetics of drug metabolism in rat liver slices. 3. Relationship between metabolic clearance and slice uptake rate. Drug Metab Dispos 25:460-467.
33. Joost HG, Holze S. 1978. Uptake of tolbutamide by islets of Langerhans and other tissues. Experientia 34:1372-1373. (Pubitemid 9030263)
34. Banks WL, Stein ER. 1965. Effect of hydrazine on protein content of various tissues in rat. Proc Soc Exp Biol Med 120:1-3.
35. Ladriere L, Malaisse Lagae F, Malaisse WJ. 2000. Uptake of tritiated glibenclamide by endocrine and exocrine pancreas. Endocrine 12:329-332. (Pubitemid 30432251)
36. Balant L. 1981. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet 6:215-241. (Pubitemid 12205060)
37. Mudaliar S, Henry RR. 2005. The oral antidiabetic agents. In: Inzucchi S, editor. The diabetes mellitus manual. 6th edition. New York: McGraw-Hill. pp. 167-201.
38. Kim KA, Park JY. 2003. Inhibitory effect of glyburide on human cytochrome P450 isoforms in human liver microsomes. Drug Metab Dispos 31:1090-1092. (Pubitemid 37048279)
39. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. 1999. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 16:1514-1519. (Pubitemid 29510546)
40. Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P. 1998. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: Comparison with other computational and experimental predictors. J Med Chem 41:5382-5392. (Pubitemid 29031322)
41. Abraham MH. 2004. The factors that influence permeation across the blood-brain barrier. Eur J Med Chem 39:235-240. (Pubitemid 38393750)
42. Potts RO, Guy RH. 1995. A predictive algorithm for skin permeability - The effects of molecular-size and hydrogen-bond activity. Pharm Res 12:1628-1633.
43. American Chemical Society. 2006. SciFinder scholar, edition. Washington, D.C.: American Chemical Society.
44. Hansch C. 1990. Comprehensive medicinal chemistry: The rational design, mechanistic study & therapeutic application of chemical compounds, edition. Oxford: Pergamon Press.